drugset
drugset / Trial / NCT05565092

Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease

NCT05565092 ↗

Phase 2 Terminated 2 enrolled Alexion Pharmaceuticals, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to assess the safety and tolerability of ALXN1820 SC (subcutaneous) in participants with SCD (Sickle Cell Disease).

Timeline

Start
2023-02-22
Primary completion
2024-01-09
Completion
2024-01-09

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision to terminate program.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Tarperprumig Monoclonal antibody 300 mg Subcutaneous
Subject Tarperprumig Monoclonal antibody 600 mg Subcutaneous

Indications

sickle cell disease